Asthma and Allergy Drug Development Is Failing Too Often–A Translational Reset Is Needed: HKEY-AIRx™1.0

2026-01-27 - 14:32

BOSTON and SUZHOU, China, Jan. 27, 2026 /PRNewswire/ — HKeyBio, a preclinical CRO focused on autoimmune and allergic disease drug development, today announced a translational preclinical strategy, HKEY-AIRxTM1.0 designed to address one of the most persistent problems facing biotech leadership: why so many asthma and allergy programs with strong preclinical data fail to deliver meaningful